MeiraGTx Holdings PLC
NASDAQ:MGTX
Intrinsic Value
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. [ Read More ]
The intrinsic value of one MGTX stock under the Base Case scenario is 45.8 USD. Compared to the current market price of 4.71 USD, MeiraGTx Holdings PLC is Undervalued by 90%.
Valuation Backtest
MeiraGTx Holdings PLC
Run backtest to discover the historical profit from buying and selling MGTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
MeiraGTx Holdings PLC
Current Assets | 159.6m |
Cash & Short-Term Investments | 129.6m |
Receivables | 23.4m |
Other Current Assets | 6.6m |
Non-Current Assets | 167.1m |
Long-Term Investments | 6.8m |
PP&E | 156.2m |
Intangibles | 1.1m |
Other Non-Current Assets | 3m |
Current Liabilities | 67.1m |
Accounts Payable | 16m |
Accrued Liabilities | 46.8m |
Other Current Liabilities | 4.2m |
Non-Current Liabilities | 121.5m |
Long-Term Debt | 72.1m |
Other Non-Current Liabilities | 49.4m |
Earnings Waterfall
MeiraGTx Holdings PLC
Revenue
|
14m
USD
|
Operating Expenses
|
-151.1m
USD
|
Operating Income
|
-137.1m
USD
|
Other Expenses
|
53m
USD
|
Net Income
|
-84m
USD
|
Free Cash Flow Analysis
MeiraGTx Holdings PLC
MGTX Profitability Score
Profitability Due Diligence
MeiraGTx Holdings PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
MeiraGTx Holdings PLC's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
MGTX Solvency Score
Solvency Due Diligence
MeiraGTx Holdings PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
MeiraGTx Holdings PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MGTX Price Targets Summary
MeiraGTx Holdings PLC
According to Wall Street analysts, the average 1-year price target for MGTX is 22.03 USD with a low forecast of 11.11 USD and a high forecast of 37.8 USD.
Ownership
MGTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MGTX Price
MeiraGTx Holdings PLC
Average Annual Return | -9.79% |
Standard Deviation of Annual Returns | 51.2% |
Max Drawdown | -88% |
Market Capitalization | 299.6m USD |
Shares Outstanding | 64 217 200 |
Percentage of Shares Shorted | 2.4% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 287 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The firm has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.
Contact
IPO
Employees
Officers
The intrinsic value of one MGTX stock under the Base Case scenario is 45.8 USD.
Compared to the current market price of 4.71 USD, MeiraGTx Holdings PLC is Undervalued by 90%.